Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIV.

Kendall EA, Durovni B, Martinson NA, Cavalacante S, Masonoke K, Saraceni V, Lebina L, Efron A, Cohn S, Chon S, Chaisson RE, Dowdy DW, Golub JE; THRio and TEKO teams.

AIDS. 2019 Sep 26. doi: 10.1097/QAD.0000000000002380. [Epub ahead of print]

PMID:
31567163
2.

Emergence of the East-Central-South-African genotype of Chikungunya virus in Brazil and the city of Rio de Janeiro may have occurred years before surveillance detection.

Souza TML, Vieira YR, Delatorre E, Barbosa-Lima G, Luiz RLF, Vizzoni A, Jain K, Miranda MM, Bhuva N, Gogarten JF, Ng J, Thakkar R, Calheiros AS, Monteiro APT, Bozza PT, Bozza FA, Tschoeke DA, Leomil L, Mendonça MCL, Rodrigues CDDS, Torres MC, Filippis AMB, Nogueira RMR, Thompson FL, Lemos C, Durovni B, Cerbino-Neto J, Morel CM, Lipkin WI, Mishra N.

Sci Rep. 2019 Feb 26;9(1):2760. doi: 10.1038/s41598-019-39406-9.

3.

Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis.

Di Tanna GL, Khaki AR, Theron G, McCarthy K, Cox H, Mupfumi L, Trajman A, Zijenah LS, Mason P, Bandason T, Durovni B, Bara W, Hoelscher M, Clowes P, Mangu C, Chanda D, Pym A, Mwaba P, Cobelens F, Nicol MP, Dheda K, Churchyard G, Fielding K, Metcalfe JZ.

Lancet Glob Health. 2019 Feb;7(2):e191-e199. doi: 10.1016/S2214-109X(18)30458-3. Erratum in: Lancet Glob Health. 2019 Apr;7(4):e419.

4.

Preventive therapy for HIV-associated tuberculosis.

Durovni B, Cavalcante S.

Curr Opin HIV AIDS. 2018 Nov;13(6):507-511. doi: 10.1097/COH.0000000000000504. Review.

PMID:
30286041
5.

Sustainable Development Goals and tuberculosis in Brazil: challenges and potentialities.

Trajman A, Saraceni V, Durovni B.

Cad Saude Publica. 2018 Jun 21;34(6):e00030318. doi: 10.1590/0102-311X00030318. English, Portuguese. No abstract available.

6.

The impact of the Brazilian Family Health Strategy and the conditional cash transfer on tuberculosis treatment outcomes in Rio de Janeiro: an individual-level analysis of secondary data.

Durovni B, Saraceni V, Puppin MS, Tassinari W, Cruz OG, Cavalcante S, Coeli CM, Trajman A.

J Public Health (Oxf). 2018 Sep 1;40(3):e359-e366. doi: 10.1093/pubmed/fdx132.

PMID:
29036661
7.

Zika in Rio de Janeiro: Assessment of basic reproduction number and comparison with dengue outbreaks.

Villela DAM, Bastos LS, DE Carvalho LM, Cruz OG, Gomes MFC, Durovni B, Lemos MC, Saraceni V, Coelho FC, Codeço CT.

Epidemiol Infect. 2017 Jun;145(8):1649-1657. doi: 10.1017/S0950268817000358. Epub 2017 Feb 27.

PMID:
28240195
8.

Higher incidence of Zika in adult women than adult men in Rio de Janeiro suggests a significant contribution of sexual transmission from men to women.

Coelho FC, Durovni B, Saraceni V, Lemos C, Codeco CT, Camargo S, de Carvalho LM, Bastos L, Arduini D, Villela DA, Armstrong M.

Int J Infect Dis. 2016 Oct;51:128-132. doi: 10.1016/j.ijid.2016.08.023. Epub 2016 Sep 21.

9.

Correction: Impact on Patients' Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial.

Trajman A, Durovni B, Saraceni V, Menezes A, Cordeiro-Santos M, Cobelens F, Van den Hof S.

PLoS One. 2016 May 24;11(5):e0156471. doi: 10.1371/journal.pone.0156471. eCollection 2016.

10.

A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.

Conde MB, Mello FC, Duarte RS, Cavalcante SC, Rolla V, Dalcolmo M, Loredo C, Durovni B, Armstrong DT, Efron A, Barnes GL, Marzinke MA, Savic RM, Dooley KE, Cohn S, Moulton LH, Chaisson RE, Dorman SE.

PLoS One. 2016 May 9;11(5):e0154778. doi: 10.1371/journal.pone.0154778. eCollection 2016.

11.

Clinical Manifestations of Zika Virus Infection, Rio de Janeiro, Brazil, 2015.

Cerbino-Neto J, Mesquita EC, Souza TM, Parreira V, Wittlin BB, Durovni B, Lemos MC, Vizzoni A, Bispo de Filippis AM, Sampaio SA, Gonçalves Bde S, Bozza FA.

Emerg Infect Dis. 2016 Jul;22(7):1318-20. doi: 10.3201/eid2207.160375. Epub 2016 Jul 15. No abstract available.

12.

Correction: Impact of Replacing Smear Microscopy with Xpert MTB/RIF for Diagnosing Tuberculosis in Brazil: A Stepped-Wedge Cluster-Randomized Trial.

Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, Menezes A, Cobelens F.

PLoS Med. 2015 Dec 3;12(12):e1001928. doi: 10.1371/journal.pmed.1001928. eCollection 2015 Dec. No abstract available.

13.

Impact on Patients' Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial.

Trajman A, Durovni B, Saraceni V, Menezes A, Cordeiro-Santos M, Cobelens F, Van den Hof S.

PLoS One. 2015 Apr 27;10(4):e0123252. doi: 10.1371/journal.pone.0123252. eCollection 2015. Erratum in: PLoS One. 2016;11(5):e0156471.

14.

Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study.

Azadi M, Bishai DM, Dowdy DW, Moulton LH, Cavalcante S, Saraceni V, Pacheco AG, Cohn S, Chaisson RE, Durovni B, Golub JE.

Int J Tuberc Lung Dis. 2014 Dec;18(12):1443-8. doi: 10.5588/ijtld.14.0108.

15.

Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial.

Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, Menezes A, Cobelens F.

PLoS Med. 2014 Dec 9;11(12):e1001766. doi: 10.1371/journal.pmed.1001766. eCollection 2014 Dec. Erratum in: PLoS Med. 2015 Dec;12(12):e1001928.

16.

Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study.

Golub JE, Cohn S, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, Durovni B, Chaisson RE.

Clin Infect Dis. 2015 Feb 15;60(4):639-45. doi: 10.1093/cid/ciu849. Epub 2014 Nov 2.

17.

High positive predictive value of Xpert in a low rifampicin resistance prevalence setting.

Trajman A, Durovni B, Saraceni V, Cordeiro-Santos M, Cobelens F, van den Hof S.

Eur Respir J. 2014 Dec;44(6):1711-3. doi: 10.1183/09031936.00115514. Epub 2014 Sep 3. No abstract available.

18.

Operational lessons drawn from pilot implementation of Xpert MTB/Rif in Brazil.

Durovni B, Saraceni V, Cordeiro-Santos M, Cavalcante S, Soares E, Lourenço C, Menezes A, van den Hof S, Cobelens F, Trajman A.

Bull World Health Organ. 2014 Aug 1;92(8):613-7. doi: 10.2471/BLT.13.131409. Epub 2014 May 1.

19.

Tuberculosis infection control: potential benefit of a new rapid tuberculosis test in a human immunodeficiency virus/AIDS reference hospital.

Cordeiro-Santos M, Trajman A, Cobelens F, Durovni B, Gonçalves M, Bührer-Sékula S, Saraceni V.

Infect Control Hosp Epidemiol. 2014 Sep;35(9):1206-7. doi: 10.1086/677643. No abstract available.

PMID:
25111939
20.

Reply to "at the crossroads between early or delayed antiretroviral therapy initiation during TB/HIV coinfection".

Saraceni V, Durovni B, Pacheco AG, Chaisson RE, Golub JE.

Braz J Infect Dis. 2014 Sep-Oct;18(5):578-9. doi: 10.1016/j.bjid.2014.07.001. Epub 2014 Aug 7. No abstract available.

21.

Applying ethical principles to international community-based research: a case study from the Consortium to Respond Effectively to the AIDS-TB Epidemic (CREATE) .

Kass NE, DeLuca AN, Coetzee L, Simwinga M, Churchyard GJ, Ayles H, Beyers N, Godfrey-Faussett P, Durovni B, Chaisson RE, Eldred LJ.

IRB. 2014 May-Jun;36(3):1-8. No abstract available.

PMID:
24946506
22.

Prevalent tuberculosis at HIV diagnosis in Rio de Janeiro, Brazil: the TB/HIV in Rio (THRio) Cohort.

Saraceni V, Cohn S, Cavalcante SC, Pacheco AG, Moulton LH, Chaisson RE, Durovni B, Golub JE.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):98-101. doi: 10.1097/QAI.0000000000000247.

23.

Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model.

Dowdy DW, Golub JE, Saraceni V, Moulton LH, Cavalcante SC, Cohn S, Pacheco AG, Chaisson RE, Durovni B.

J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):552-8. doi: 10.1097/QAI.0000000000000219.

24.

Survival of HIV patients with tuberculosis started on simultaneous or deferred HAART in the THRio cohort, Rio de Janeiro, Brazil.

Saraceni V, Durovni B, Cavalcante SC, Cohn S, Pacheco AG, Moulton LH, Chaisson RE, Golub JE.

Braz J Infect Dis. 2014 Sep-Oct;18(5):491-5. doi: 10.1016/j.bjid.2014.02.004. Epub 2014 Apr 27.

25.

Tuberculosis control in a socially vulnerable area: a community intervention beyond DOT in a Brazilian favela.

Soares EC, Vollmer WM, Cavalcante SC, Pacheco AG, Saraceni V, Silva JS, Neves GR, Golub JE, Efron AR, Durovni B, Chaisson RE.

Int J Tuberc Lung Dis. 2013 Dec;17(12):1581-6. doi: 10.5588/ijtld.13.0152.

PMID:
24200272
26.

Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.

Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, Cohn S, Efron A, Chaisson RE, Golub JE.

Lancet Infect Dis. 2013 Oct;13(10):852-8. doi: 10.1016/S1473-3099(13)70187-7. Epub 2013 Aug 16.

27.

Quality of life among people treated for tuberculosis and human immunodeficiency virus in Rio de Janeiro, Brazil.

Dowdy DW, Israel G, Vellozo V, Saraceni V, Cohn S, Cavalcante S, Chaisson RE, Golub JE, Durovni B.

Int J Tuberc Lung Dis. 2013 Mar;17(3):345-7. doi: 10.5588/ijtld.12.0123. Epub 2013 Jan 14.

28.

Physician adherence to guidelines for tuberculosis and HIV care in Rio de Janeiro, Brazil.

Saraceni V, Pacheco AG, Golub JE, Vellozo V, King BS, Cavalcante SC, Eldred L, Chaisson RE, Durovni B.

Braz J Infect Dis. 2011 May-Jun;15(3):249-52.

29.

The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.

Durovni B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, King BS, Cohn S, Efron A, Pacheco AG, Moulton LH, Chaisson RE, Golub JE.

AIDS. 2010 Nov;24 Suppl 5:S49-56. doi: 10.1097/01.aids.0000391022.95412.a6.

30.

Isoniazid preventive therapy for HIV-infected people: evidence to support implementation.

Eldred LJ, Churchyard G, Durovni B, Godfrey-Faussett P, Grant AD, Getahun H, Chaisson RE.

AIDS. 2010 Nov;24 Suppl 5:S1-3. doi: 10.1097/01.aids.0000391009.95149.ec. No abstract available.

PMID:
21079422
31.

Estimating the extent of underreporting of mortality among HIV-infected individuals in Rio de Janeiro, Brazil.

Pacheco AG, Saraceni V, Tuboi SH, Lauria LM, Moulton LH, Faulhaber JC, King B, Golub JE, Durovni B, Cavalcante S, Harrison LH, Chaisson RE, Schechter M.

AIDS Res Hum Retroviruses. 2011 Jan;27(1):25-8. doi: 10.1089/aid.2010.0089. Epub 2010 Oct 7.

32.

Controlled trial of active tuberculosis case finding in a Brazilian favela.

Miller AC, Golub JE, Cavalcante SC, Durovni B, Moulton LH, Fonseca Z, Arduini D, Chaisson RE, Soares EC.

Int J Tuberc Lung Dis. 2010 Jun;14(6):720-6.

33.

Community-randomized trial of enhanced DOTS for tuberculosis control in Rio de Janeiro, Brazil.

Cavalcante SC, Durovni B, Barnes GL, Souza FB, Silva RF, Barroso PF, Mohan CI, Miller A, Golub JE, Chaisson RE.

Int J Tuberc Lung Dis. 2010 Feb;14(2):203-9.

34.

III Brazilian Thoracic Association Guidelines on tuberculosis.

Conde MB, Melo FA, Marques AM, Cardoso NC, Pinheiro VG, Dalcin Pde T, Machado Junior A, Lemos AC, Netto AR, Durovni B, Sant'Anna CC, Lima D, Capone D, Barreira D, Matos ED, Mello FC, David FC, Marsico G, Afiune JB, Silva JR, Jamal LF, Telles MA, Hirata MH, Dalcolmo MP, Rabahi MF, Cailleaux-Cesar M, Palaci M, Morrone N, Guerra RL, Dietze R, Miranda SS, Cavalcante SC, Nogueira SA, Nonato TS, Martire T, Galesi VM, Dettoni Vdo V; BTA Committee on Tuberculosis; BTA Guidelines on Tuberculosis Work Group.

J Bras Pneumol. 2009 Oct;35(10):1018-48. Review. English, Portuguese.

35.

Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults.

Dowdy DW, Lourenço MC, Cavalcante SC, Saraceni V, King B, Golub JE, Bishai D, Durovni B, Chaisson RE, Dorman SE.

PLoS One. 2008;3(12):e4057. doi: 10.1371/journal.pone.0004057. Epub 2008 Dec 29.

36.

Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil.

Golub JE, Durovni B, King BS, Cavalacante SC, Pacheco AG, Moulton LH, Moore RD, Chaisson RE, Saraceni V.

AIDS. 2008 Nov 30;22(18):2527-33. doi: 10.1097/QAD.0b013e328311ac4e.

37.

Validation of a hierarchical deterministic record-linkage algorithm using data from 2 different cohorts of human immunodeficiency virus-infected persons and mortality databases in Brazil.

Pacheco AG, Saraceni V, Tuboi SH, Moulton LH, Chaisson RE, Cavalcante SC, Durovni B, Faulhaber JC, Golub JE, King B, Schechter M, Harrison LH.

Am J Epidemiol. 2008 Dec 1;168(11):1326-32. doi: 10.1093/aje/kwn249. Epub 2008 Oct 9.

38.

AIDS-related tuberculosis in Rio de Janeiro, Brazil.

Pacheco AG, Durovni B, Cavalcante SC, Lauria LM, Moore RD, Moulton LH, Chaisson RE, Golub JE.

PLoS One. 2008 Sep 10;3(9):e3132. doi: 10.1371/journal.pone.0003132.

39.

Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil.

Saraceni V, King BS, Cavalcante SC, Golub JE, Lauria LM, Moulton LH, Chaisson RE, Durovni B.

Int J Tuberc Lung Dis. 2008 Jul;12(7):769-72.

40.

The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.

Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B.

AIDS. 2007 Jul 11;21(11):1441-8.

41.

Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention.

Moulton LH, Golub JE, Durovni B, Cavalcante SC, Pacheco AG, Saraceni V, King B, Chaisson RE.

Clin Trials. 2007;4(2):190-9.

PMID:
17456522
42.

Community DOT for tuberculosis in a Brazilian favela: comparison with a clinic model.

Cavalcante SC, Soares EC, Pacheco AG, Chaisson RE, Durovni B; DOTS Expansion Team.

Int J Tuberc Lung Dis. 2007 May;11(5):544-9.

PMID:
17439679
43.

Tuberculosis as a disease defining acquired immunodeficiency syndrome: ten years of surveillance in Rio de Janeiro, Brazil.

Soares EC, Saraceni V, Lauria Lde M, Pacheco AG, Durovni B, Cavalcante SC.

J Bras Pneumol. 2006 Sep-Oct;32(5):444-8. English, Portuguese.

44.

Occupational exposures to bloodborne pathogens among healthcare workers in Rio de Janeiro, Brazil.

Rapparini C, Saraceni V, Lauria LM, Barroso PF, Vellozo V, Cruz M, Aquino S, Durovni B.

J Hosp Infect. 2007 Feb;65(2):131-7. Epub 2006 Dec 18.

PMID:
17178428
45.

Improvements in treatment success rates with directly observed therapy in Rio de Janeiro City.

Soares EC, Pacheco AG, Mello FC, Durovni B, Chaisson RE, Cavalcante SC.

Int J Tuberc Lung Dis. 2006 Jun;10(6):690-5.

PMID:
16776458
46.

Trends and characteristics of AIDS mortality in the Rio de Janeiro city after the introduction of highly active antiretroviral therapy.

Saraceni V, da Cruz MM, Lauria Lde M, Durovni B.

Braz J Infect Dis. 2005 Jun;9(3):209-15. Epub 2005 Oct 3.

PMID:
16224627
47.

AIDS case definitions in developing countries.

Durovni B, Pinto M, Schecter M.

Lancet. 1993 Oct 23;342(8878):1054. No abstract available.

PMID:
8105285

Supplemental Content

Loading ...
Support Center